Treating depression seen important in heart failure Canada.com, Canada - NEW YORK (Reuters Health) - Depression increases the risk of death in patients with heart failure, but the risk apparently disappears with antidepressant ...
MicroRNA Blocker Prevented Heart Failure In Mice Medical News Today, UK - They also targeted miR-21 and prevented heart failure in laboratory mice by using a new experimental drug called antisense oligonucleotide (an anti- miR-21 ...
Near death ruminations BusinessWorld Online, Philippines - For the second time I was at the verge of a heart failure. The first time was 13 years ago. My cardiologist informed me after the crisis that I was seven ...
Avandia Label Had Data on Congestive Heart Failure Wall Street Journal - Nov 27, 2008 The label for the diabetes drug Avandia already contained information about congestive heart failure at the time a Maryland physician raised concerns ...
Iron overload can lead to diabetes, heart failure The Plain Dealer - cleveland.com, OH - Aug 5, 2008 Over time, the toxic effects of the excess iron can lead to damaging diseases like diabetes, congestive heart failure, and endocrine system problems. ...
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure - M Packer, MR Bristow, JN Cohn, WS Colucci, MB … - The New England Journal of Medicine, 1996 - nejm.org The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. ... Pure heart rate reduction: further perspectives in heartfailure. ... -
Cardiac Resynchronization in Chronic Heart Failure - WT Abraham, WG Fisher, AL Smith, DB Delurgio, AR … - New England Journal of Medicine, 2002 - content.nejm.org Cardiac Resynchronization in Chronic HeartFailure. William T. Abraham, MD, Westby
G. Fisher, MD, Andrew L. Smith, MD, David B. Delurgio, MD, Angel R. Leon, MD ...
Effect of Carvedilol on Survival in Severe Chronic Heart Failure - M Packer, AJS Coats, MB Fowler, HA Katus, H Krum, … - New England Journal of Medicine - content.nejm.org Effect of Carvedilol on Survival in Severe Chronic HeartFailure. Milton Packer,
MD, Andrew JS Coats, MD, Michael B. Fowler, MD, Hugo A. Katus, MD, Henry Krum ...
The epidemiology of heart failure: the Framingham Study. - KK Ho, JL Pinsky, WB Kannel, D Levy - J Am Coll Cardiol, 1993 - ncbi.nlm.nih.gov The epidemiology of heartfailure: the Framingham Study. Ho KK, Pinsky JL, Kannel
WB, Levy D. Charles A. Dana Research Institute, Boston, Massachusetts. ...
Is the prognosis of heart failure improving? - JGF Cleland, I Gemmell, A Khand, A Boddy - European Journal of Heart Failure, 1999 - Elsevier ? . European Journal of HeartFailure 1 1999 229 241 Is the prognosis of heartfailure
improving? ... 13508 15684 21189 heartfailure in the index year Total no. ...
Source: Google Scholar
HEART FAILURE
Success at staving off disease may vary with medication type.
THE QUESTION: High blood pressure often leads to heart failure, so treating hypertension is considered a prime means of prevention. Does it matter what type of blood-pressure drug is used?
THIS STUDY analyzed medical data on 33,357 people who had participated in a study comparing antihypertensive drugs. Participants were at least 55 years old and had hypertension and at least one other risk factor for heart disease, such as being diabetic or a smoker. They had been randomly assigned to take a diuretic (chlorthalidone), a calcium channel blocker (amlodipine) or an ACE inhibitor (lisinopril). During a five-year period, 1,773 people were diagnosed with heart failure. During the first year after treatment, people who took a channel blocker or ACE inhibitor were more than twice as likely to have been hospitalized for heart failure or to have died from it as were those who took a diuretic. By the fifth year, those in the channel blocker group were 22 percent more likely than the others to have had serious heart failure.
WHO MAY BE AFFECTED BY THESE FINDINGS? People with high blood pressure. An estimated 90 percent of people with heart failure had high blood pressure first.
CAVEATS: To control their blood pressure, most participants were given additional drugs as the study progressed; this may have affected the findings. The study was funded by Pfizer, which also provided medications, as did AstraZeneca and Bristol-Myers Squibb. Three of the 15 main authors had received fees from the companies.
FIND THIS STUDY: May 9 issue of Circulation; abstract available online at www.circulationaha.org.
An added procedure may diminish incontinence risk.
THE QUESTION: Weakened pelvic muscles can cause the uterus to sag and sometimes protrude through the vaginal opening. To correct this, women usually have surgery, called sacrocolpopexy. Afterward, however, coughing or sneezing often causes urine leakage. To prevent this so-called stress incontinence, might it help to have an additional procedure at the time of surgery, suturing the vagina to a pelvic ligament?
THIS STUDY randomly assigned about half of 322 women undergoing sacrocolpopexy to have a second procedure, a Burch colposuspension, at the same time. Three months later, 44 percent of the women who had only the surgery reported symptoms of stress incontinence, compared with 24 percent of those who also had the Burch procedure. About four times more women in the surgery-only group than in the Burch group reported the most bothersome symptoms.
WHO MAY BE AFFECTED BY THESE FINDINGS? Women with pelvic-organ prolapse, which can occur after frequent childbirth or with aging. More than 200,000 women in the United States have prolapse surgery each year.
CAVEATS: Surgeries lasted about 12 percent longer when they included the Burch procedure. Long-term effectiveness remains unknown. Whether the findings apply to women who have different surgical procedures for prolapse or incontinence remains unclear.
FIND THIS STUDY: April 13 issue of the New England Journal of Medicine; abstract available online at www.nejm.org (scroll to bottom of screen and click on "past issues," then select "2006," then select the April 13 issue.
